CCR2-RA-[R] |
Catalog No.GC31714 |
CCR2-RA -[R] can inhibit CCR2 in a non-competitive binding manner, mainly by blocking activation-related conformational changes and the formation of G-protein binding interfaces.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 512177-83-2
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment [1]: | |
Preparation Method |
For dissociation experiments, the membranes were first incubated with 3 nM CCR2-RA-[R]CCR2-RA-[R] for 90 minutes. Dissociation was initiated by the addition of 10 mM of JNJ-27141491 at different time points. |
Reaction Conditions |
3 nM [3H]CCR2-RA-[R] for 90 minutes |
Applications |
CCR2-RA-[R] had IC50 values of 103 + 18. Saturation binding experiments yielded a Kp of 5.8 + 0.2 nM with a Bmax of 9.7 + 0.2 pmol/mg. |
Cell experiment [1]: | |
Cell lines |
U2OS-CCR2 cells |
Preparation Method |
For the antagonist assays, cells were first preincubated for 30 minutes with increasing concentrations of antagonist(including CCR2-RA-[R]) or vehicle control that was added in 5 ul of compound solution (final concentration of 0.25% dimethylsulfoxide).Subsequently, cells were stimulated with an ECso concentration (3 nM) of CCL2. |
Reaction Conditions |
Increasing concentrations of the antagonists(including CCR2-RA-[R] were added 30 minutes before agonist stimulation to determine their IC 50 value.( No specific concentration) |
Applications |
INCB3344 competitively inhibited CCL2-induced G protein activation, whereas CCR2-RA-[R] showed a noncompetitive or allosteric mode of inhibition. |
Animal experiment [2]: | |
Animal models |
Adult female Sprague-Dawley rats (150-200 g) |
Preparation Method |
CCR2-RA-[R] were given a one-time intraperitoneal (i.p.) injection one hour prior to behavioral testing. |
Dosage form |
10 mg/kg CCR2-RA-[R] for 1 time |
Applications |
CCR2-RA-[R] treatment of nerve-injured rats produced stereospecific bilateral reversal of tactile hyperalgesia |
References: [1]. Zweemer AJ, Nederpelt I, ,et,al. Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2. Mol Pharmacol. 2013 Oct;84(4):551-61. doi: 10.1124/mol.113.086850. Epub 2013 Jul 22. PMID: 23877010. |
CCR2-RA -[R] can inhibit CCR2 in a non-competitive binding manner, mainly by blocking activation-related conformational changes and the formation of G-protein binding interfaces[1,2]. For CCR2-RA-[R] the most important residues for binding were found to be the highly conserved tyrosine Y(7.53) and phenylalanine F(8.50) of the NPxxYx(5,6)F motif, as well as V(6.36) at the bottom of TM-VI and K(8.49) in helix-VIII[3].
CCR2-RA-[R] had IC50 values of 103 nM.Saturation binding experiments yielded a Kp of 5.8 + 0.2 nM with a Bmax of 9.7 + 0.2 pmol/mg.CCR2-RA-[R] clearly showed noncompetitive antagonism for CCR2 with respect to CCL2, as indicated by a decrease in CCL2's efficacy in the presence of increasing concentrations of CCR2RA-[R][1].
Focal nerve demyelination increased behavioral reflex responsiveness to mechanical stimuli between postoperative day (POD) 3 and POD28 in both the hindpaw ipsilateral and contralateral to the nerve injury. CCR2 RA-[R] treatment of nerve-injured rats produced stereospecific bilateral reversal of tactile hyperalgesia[4]. CCR2i CCR2-RA-[R] (MCP-1 receptor inhibitor) were administered via intraperitoneal injection. With or without PDX, treatment with CCR2-RA-[R] reduced the number of neutrophils and recruited macrophages, indicating that the basic function of PDX was disappeared after using CCR2 inhibitors(CCR2-RA-[R])[5]. CCR2 RA-[R] enhances the response to ¨»PD-1 by promoting the counts of progenitor Tex[6]. Compared to the model group, the fluorescence intensity of spleen was markedly decreased by Pirfenidone and CCR2-RA-[R] Moreover, Compared to the model group, the fluorescence intensity of liver metastasis foci was dramatically reduced by Pirfenidone and CCR2-RA-[R][7].
References:
[1]. Zweemer AJ, Nederpelt I,et,al. Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2. Mol Pharmacol. 2013 Oct;84(4):551-61. doi: 10.1124/mol.113.086850. Epub 2013 Jul 22. PMID: 23877010.
[2]. Zheng Y, Qin L, ,et,al.Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature. 2016 Dec 15;540(7633):458-461. doi: 10.1038/nature20605. Epub 2016 Dec 7. PMID: 27926736; PMCID: PMC5159191.
[3]. Zweemer AJ, Bunnik J, ,et,al.Discovery and mapping of an intracellular antagonist binding site at the chemokine receptor CCR2. Mol Pharmacol. 2014 Oct;86(4):358-68. doi: 10.1124/mol.114.093328. Epub 2014 Jul 14. PMID: 25024169.
[4]. Bhangoo S, Ren D, ,et,al. Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors. Mol Pain. 2007 Dec 12;3:38. doi: 10.1186/1744-8069-3-38. PMID: 18076762; PMCID: PMC2228278.
[5]. Ye Y, Zhang HW, et,al. PDX regulates inflammatory cell infiltration via resident macrophage in LPS-induced lung injury. J Cell Mol Med. 2020 Sep;24(18):10604-10614. doi: 10.1111/jcmm.15679. Epub 2020 Jul 31. PMID: 32735065; PMCID: PMC7521295.
[6]. Yihua Xu, Hao Wang, et,al. DFB Suppresses Obesity-Driven CRC Via Restricting Progenitor to Terminally Exhausted T Cell Differentiation, 19 October 2021, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-952538/v1]
[7]. Chen C, Yao X, et,al. Dahuang Zhechong Pill suppresses colorectal cancer liver metastasis via ameliorating exosomal CCL2 primed pre-metastatic niche. J Ethnopharmacol. 2019 Jun 28;238:111878. doi: 10.1016/j.jep.2019.111878. Epub 2019 Apr 13. PMID: 30986521.
Cas No. | 512177-83-2 | SDF | |
Canonical SMILES | O=C1C(O)=C(C(C)=O)[C@@H](C2CCCCC2)N1C(C(F)=C3)=CC=C3Cl | ||
Formula | C18H19ClFNO3 | M.Wt | 351.8 |
Solubility | DMSO : ≥ 125 mg/mL (355.32 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.8425 mL | 14.2126 mL | 28.4252 mL |
5 mM | 0.5685 mL | 2.8425 mL | 5.685 mL |
10 mM | 0.2843 mL | 1.4213 mL | 2.8425 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 26 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *